Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ABBV-901 Monotherapy and ABBV-901 + Bevacizumab in Ovarian Cancer
jRCT2041250139Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of cusp06 in Serous Papillary Cystadenocarcinoma, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (6 arms), sponsored by AbbVie Inc. Started Dec 2025; status: recruiting.
02
Drugs
cusp06
03
Conditions
Serous Papillary Cystadenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2041250139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250139.